lancet semaglutide The argued that 2026 could become a turning point for obesity treatment because patents are expiring in several countries. That could open the door to cheaper biosimilars for a huge Semaglutide protects heart beyond weight

Semaglutide 2.4 mg injection (Wegovy , Novo Nordisk ), a glucagon-like peptide-1 (GLP-1) receptor agonist, was approved in June 2021 for chronic weight management in adults with overweight and 1 weight-related condition or obesity based on demonstrated weight reduction in clinical trials [10]

Do not purchase it from online pharmacies or peptide research sites these products are unregulated and potentially dangerous

Today, compounded semaglutide from licensed 503A pharmacies provides an accessible path to this proven therapy

Patients should be informed about symptoms like severe abdominal pain (a sign of pancreatitis), persistent nausea or vomiting, and any unusual changes in heart rate or blood sugar levels